Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710. USA; Center on Health and Society, Duke University, Durham, NC, USA.
Hillsborough, NC 27278, USA.
Med Hypotheses. 2020 Nov;144:109880. doi: 10.1016/j.mehy.2020.109880. Epub 2020 May 25.
Fever has been reported as a common symptom occurring in COVID-19 illness. Over the counter antipyretics such as ibuprofen and acetaminophen are often taken by individuals to reduce the discomfort of fever. Recently, the safety of ibuprofen in COVID-19 patients has been questioned due to anecdotal reports of worsening symptoms in previously healthy young adults. Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen. As fever may have benefit in shortening the duration of viral illness, it is plausible to hypothesize that the antipyretic efficacy of ibuprofen may be hindering the benefits of a fever response when taken during the early stages of COVID-19 illness.
发热是 COVID-19 疾病的常见症状。为了减轻发热引起的不适,人们常自行服用布洛芬和对乙酰氨基酚等非处方退热剂。最近,由于有传闻称先前健康的年轻成年人的症状恶化,布洛芬在 COVID-19 患者中的安全性受到质疑。研究表明,布洛芬在退热方面比对乙酰氨基酚更有效。由于发热可能有助于缩短病毒感染的持续时间,因此可以合理假设,在 COVID-19 疾病早期服用布洛芬会阻碍发热反应的益处,从而降低其退热效果。